2025年国家医保目录现场谈判及商保创新药目录价格协商将于本周在北京举行

Core Insights - The National Medical Insurance Directory negotiations and commercial insurance innovative drug directory price negotiations will take place this week in Beijing, with multiple domestic and international pharmaceutical companies sending teams to participate [1] Group 1: National Medical Insurance Directory - This year's negotiations continue the regular adjustment mechanism of the medical insurance directory while officially introducing the "commercial insurance innovative drug directory" mechanism for the first time [1] - A total of 535 drugs have passed the formal review for this round of negotiations, setting a new record for the highest number of approved drugs in history [1] - The approved drugs include significant domestic new drugs such as Heng Rui Medicine's Ruilong Qutuzumab and Kelun Biotech's Lukan Sandotuzumab, as well as important products from multinational pharmaceutical companies like Eli Lilly, Janssen, and AstraZeneca [1] Group 2: Commercial Insurance Innovative Drug Directory - Additionally, 121 drugs have passed the review for the commercial insurance innovative drug directory [1]